Clinical trials: Aromatase Inhibitors
Osteoporosis, Osteoporosis Fracture
Breast Cancer Women on Aromatase Inhibitors Treatment
The main objective of the study is to improve the life quality of women treated with AI. Cohort B-ABLE is designed to evaluate musculoskeletal events derived of using AI in breast cancer women.
- Conditions
- Osteoporosis, Osteoporosis Fracture, Arthralgia Generalized
- Trial name
- B-ABLE (NCT03811509)
- Testing
- bisphosphonate
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Parc de Salut Mar
Ovarian Cancer
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
In this Italian, multicenter, randomized, double-blind, placebo controlled, phase III study the efficacy of exemestane will be evaluated in addition to the standard front line treatment in patients with hormone-receptor-positive…
- Trial name
- EXPERT (NCT04460807)
- Testing
- Exemestane
- Where
- 47 sites in Italy
- Volunteers
- 23 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Breast Cancer
Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
The investigators are hypothesizing that decreasing estrogen levels will cause serum DKK1 to peak, then decrease gradually as estrogens reach a new lower, but steady level.
- Trial name
- NCT01431872
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Arkansas
Breast Cancer
Adjuvant Post-Tamoxifen Exemestane Trial
The ATENA phase III randomized parallel-group multicenter trial is designed to compare 5 years of adjuvant exemestane versus 5 years of observation in postmenopausal women with operable breast cancer who have received 5-7 years…
- Trial name
- ATENA (NCT00810706)
- Testing
- exemestane
- Where
- Greece
- Volunteers
- 448 people
- Sponsor
- Hellenic Breast Surgeons Society
Anovulation
Administration of Single High Dose Letrozole for Ovulation Induction
Letrozole is considered an established treatment for ovulation induction.The most common protocol is daily dose of 2.5-7.5 mg starting day 3-5 of the cycle for 5 days.Another described protocol is single high dose 20mg Letrozole…
- Trial name
- NCT02703649
- Testing
- Letrozole
- Where
- 2 sites in Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
to Evaluate Letrozole as a Modality for Minimal Ovarian Stimulation in ICSI Cycles .
Letrozole in Assisted Reproductive Technology
Infertility in not a health problem and that infertile couples are not really ill. However, this narrow interpretation of the problem is refuted by the world community.
- Trial name
- NCT02429999
- Testing
- Letrezole plus FSH, Standard protocol for induction of ovulation
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Menstruation Disorders
Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers
Aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent breast cancer. They act by blocking the action of the enzyme, aromatase, that is necessary for the production of estradiol.
- Trial name
- NCT00467493
- Testing
- Anastrozole
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Meditrina Pharmaceuticals
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with letrozole (Femara) and of XL765 when given in combination with letrozole.
- Trial name
- NCT01082068
- Testing
- XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara)
- Where
- 17 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- Sanofi
Breast Cancer
Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer
Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the important mechanisms for suppressing tumors of Trastuzumab. Pre-clinical data suggest that the ADCC effect of Inetetamab, an anti-HER2 monoclonal antibody with a…
- Trial name
- Increase (NCT04941885)
- Testing
- Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Musculoskeletal Health
A Cohort Study of Musculoskeletal Health in Patients With Breast Cancer During Aromatase Inhibitors Therapy
Postmenopausal women with hormone receptor-positive breast cancer are now prescribed aromatase inhibitors with 5 years or longer durations of therapy as recommended by clinical guidelines, which contributes to reducing breast…
- Trial name
- NCT05921617
- Testing
- No intervention
- Where
- China
- Volunteers
- 870 people
- Sponsor
- Fudan University
Breast Neoplasms, Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS)
Evidence-Based Practice for the Management of Musculoskeletal Symptoms in Breast Cancer Patients Undergoing Endocrine Therapy: A Multicultural Perspective
The purpose of this implementation study is to evaluate the application of an evidence-based practice (EBP) program for managing musculoskeletal symptoms in breast cancer patients receiving endocrine therapy, from a multicultural…
- Trial name
- EBP-MS-BC (NCT07500038)
- Testing
- Culturally Adapted EBP Program, Standard Routine Care
- Where
- China
- Volunteers
- 289 people
- Sponsor
- Yuling CAO
Carcinoma Breast Stage IV
Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline.
- Trial name
- NCT02161315
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Invasive Breast Cancer
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.
- Trial name
- NCT03219476
- Testing
- Anastrozole, Letrozole, Exemestane
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer, Joint Pain
Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease
This phase I trial studies how well curcumin works in reducing joint pain in patients who are breast cancer survivors and have joint disease caused by treatment with aromatase inhibitors.
- Trial name
- NCT03865992
- Testing
- Curcumin, Nanoemulsion, Quality-of-Life Assessment
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Genetic Predictors to Acupuncture Response for Arthralgia Induced by Aromatase Inhibitors in Patients With Breast Cancer
Purpose:Acupuncture for arthralgia induced by aromatase inhibitors in patients with breast cancer associated with screening of SNPs.
- Trial name
- NCT05125432
- Testing
- Acupuncture group
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Affiliated Hospital of Qinghai University
Muscle Pain, Joint Pain
Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors
The Purpose of this study is to determine whether vitamin D3 supplements will decrease the muscle and bone pain that are reported by women who take Aromatase Inhibitors.
- Trial name
- NCT01509079
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- HealthPartners Institute
Periodontal Disease, Quality of Life
Oral Health in Breast Cancer Survivors on Aromatase Inhibitors
The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life.
- Trial name
- NCT01693731
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Breast Neoplasms
Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
This non-interventional study will be conducted in several Eastern European countries to assess the safety, tolerability and efficacy of Aromasin® when it is administered in real-word setting in postmenopausal women with invasive…
- Trial name
- NCT01239745
- Testing
- Aromasin
- Where
- 11 sites in Croatia, Estonia and 1 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Endocrine Responsive Early Breast Cancer
Impact of Adjuvant Treatment With Aromatase Inhibitor on Sleep Disturbances in Postmenopausal Women With Endocrine Responsive Early Breast Cancer
Insomnia is common in Breast cancer patients during adjuvant therapy with aromatase inhibitor. However it is difficult to establish whether it is due to the knowledge of the disease or the treatment administred.
- Trial name
- NCT02166281
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia